{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,25]],"date-time":"2026-06-25T04:49:06Z","timestamp":1782362946409,"version":"3.54.5"},"reference-count":19,"publisher":"Media Sphere Publishing Group","issue":"8","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Z. nevrol. psikhiatr. im. S.S. Korsakova"],"published-print":{"date-parts":[[2021]]},"DOI":"10.17116\/jnevro202112108130","type":"journal-article","created":{"date-parts":[[2021,9,6]],"date-time":"2021-09-06T07:25:05Z","timestamp":1630913105000},"page":"30","source":"Crossref","is-referenced-by-count":2,"title":["Pharmacoeconomic aspects of using cladribine (in tablets) for treatment of adult patients with remitting multiple sclerosis"],"prefix":"10.17116","volume":"121","author":[{"given":"N.A.","family":"Avxentyev","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.V.","family":"Davydovskaya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Y.V.","family":"Makarova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.Yu.","family":"Frolov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.L.","family":"Klabukova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"6743","reference":[{"key":"key-10.17116\/jnevro202112108130-1","unstructured":"Gusev EI, Boiko AN, Stolyarov ID. Rasseyannyi skleroz. Spravochnik. M.: Real Taim; 2009. (In Russ)"},{"key":"key-10.17116\/jnevro202112108130-2","unstructured":"Polikarpov AV, Aleksandrova GA, Golubev NA, Tjurina EM, Os\u2019kov JuI, Shelepova EA. Zabolevaemost\u2019 vsego naselenija Rossii v 2019 godu. Statisticheskie materialy. Chast\u2019 II. M. 2020. Accessed April 29, 2021. (In Russ). https:\/\/last.mednet.ru\/images\/materials\/statistika\/2020\/2020_v2\/01_zabolevaemost_vsego_naseleniya_rossii_v_2019_godu_81a70.doc"},{"key":"key-10.17116\/jnevro202112108130-3","doi-asserted-by":"publisher","DOI":"10.1177\/135245850000600303"},{"key":"key-10.17116\/jnevro202112108130-4","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1601277"},{"key":"key-10.17116\/jnevro202112108130-5","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(12)61768-1"},{"key":"key-10.17116\/jnevro202112108130-6","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa044397"},{"key":"key-10.17116\/jnevro202112108130-7","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0909494"},{"key":"key-10.17116\/jnevro202112108130-8","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(14)70049-3"},{"key":"key-10.17116\/jnevro202112108130-9","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(12)61769-3"},{"key":"key-10.17116\/jnevro202112108130-10","unstructured":"Ziryanov SK, Dyakov YN. A clinical-economic evaluation of alemtuzumab in relapsing-remitting multiple sclerosis. Klinicheskaya farmakologiya i terapiya. 2017;26(2):93-96. Accessed April 29, 2021. (In Russ). https:\/\/clinpharm-journal.ru\/files\/articles\/kliniko-ekonomicheskaya-otsenka-alemtuzumaba-pri-retsidiviruyushhem-remittiruyushhem-rasseyannom-skleroze.pdf"},{"key":"key-10.17116\/jnevro202112108130-11","unstructured":"Rasseyannyi skleroz. Proekt klinicheskikh rekomendatsii vserossiiskogo obshchestva nevrologov. \u2014 2019. Accessed April 29, 2021. (In Russ)"},{"key":"key-10.17116\/jnevro202112108130-12","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0902533"},{"key":"key-10.17116\/jnevro202112108130-13","doi-asserted-by":"publisher","DOI":"10.1177\/1352458517727603"},{"key":"key-10.17116\/jnevro202112108130-14","unstructured":"Postanovlenie Pravitel\u2019stva RF ot 28.08.14 No. 871 (red. ot 03.12.20) \u00abOb utverzhdenii Pravil formirovaniya perechnei lekarstvennykh preparatov dlya meditsinskogo primeneniya i minimal\u2019nogo assortimenta lekarstvennykh preparatov, neobkhodimykh dlya okazaniya meditsinskoi pomoshchi\u00bb. Accessed April 29, 2021. (In Russ.). https:\/\/www.consultant.ru\/document\/cons_doc_LAW_167999\/"},{"key":"key-10.17116\/jnevro202112108130-15","doi-asserted-by":"publisher","DOI":"10.1080\/03007995.2017.1407303"},{"key":"key-10.17116\/jnevro202112108130-16","doi-asserted-by":"publisher","DOI":"10.1080\/03007995.2019.1585779"},{"key":"key-10.17116\/jnevro202112108130-17","doi-asserted-by":"publisher","DOI":"10.1111\/ene.12304"},{"key":"key-10.17116\/jnevro202112108130-18","unstructured":"Postanovlenie Pravitel\u2019stva RF ot 28 dekabrya 2020 g. No. 2299 \u00abO Programme gosudarstvennykh garantii besplatnogo okazaniya grazhdanam meditsinskoi pomoshchi na 2021 god i na planovyi period 2022 i 2023 godov\u00bb. Accessed April 29, 2021. (In Russ.). https:\/\/government.ru\/news\/41272\/"},{"key":"key-10.17116\/jnevro202112108130-19","unstructured":"Metodicheskie rekomendatsii po sposobam oplaty meditsinskoi pomoshchi za schet sredstv obyazatel\u2019nogo meditsinskogo strakhovaniya ot 30 dekabrya 2020 goda No. 11-7\/and\/2-20691. Accessed April 29, 2021. (In Russ.). https:\/\/docs.cntd.ru\/document\/573326864"}],"container-title":["Zhurnal nevrologii i psikhiatrii im. S.S. Korsakova"],"original-title":[],"language":"en","deposited":{"date-parts":[[2021,9,6]],"date-time":"2021-09-06T07:25:47Z","timestamp":1630913147000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.mediasphera.ru\/issues\/zhurnal-nevrologii-i-psikhiatrii-im-s-s-korsakova\/2021\/8\/1199772982021081030"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021]]},"references-count":19,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2021]]}},"alternative-id":["10.17116\/jnevro202112108130"],"URL":"https:\/\/doi.org\/10.17116\/jnevro202112108130","relation":{},"ISSN":["1997-7298"],"issn-type":[{"value":"1997-7298","type":"print"}],"subject":[],"published":{"date-parts":[[2021]]}}}